Cutera, Inc. - CUTR STOCK NEWS

Cutera has launched AviClear, the first FDA-cleared energy-based device for treating acne, across North America. A survey shows 90% of acne sufferers believe clear skin would significantly enhance their lives. Many respondents reported missing important life events due to their condition. The CEO emphasized the emotional impact of acne and expressed enthusiasm for AviClear's potential to help patients regain confidence. The company is planning a measured expansion of AviClear providers throughout 2022, aiming to redefine acne treatment.

Cutera, Inc. announced the pricing of $210 million in 2.25% convertible senior notes due 2028. The offering is aimed at qualified institutional buyers, with a closing date expected on May 27, 2022. The notes bear a 2.25% interest rate, maturing on June 1, 2028, and convertible into cash or shares of Cutera's common stock at the company's discretion. The offering is projected to generate approximately $202.8 million in net proceeds, intended for capped call transactions, Notes Exchange, and general corporate purposes, including potential acquisitions.

Cutera, Inc. (CUTR) plans to offer up to $200 million in convertible senior notes due 2028, pending market conditions, through a private placement for qualified institutional buyers. An additional $30 million may be offered if initial purchasers exercise their option. The funds will primarily support capped call transactions, a notes exchange, and general corporate purposes, including potential acquisitions. Notably, affiliated entities may purchase up to $10 million in the notes. These notes will be unsecured and convertible into cash and/or Cutera's common stock.

Cutera (CUTR) reported a strong 17% revenue growth for Q1 2022, reaching $58 million. This increase rose to 21% when adjusted for constant currency, fueled by robust North American performance. Capital Equipment revenue surged by 29% to $36.5 million. However, operating expenses escalated to $44.9 million, resulting in a GAAP net loss of $15.1 million, compared to a slight loss in the prior year. The company maintained its full-year revenue guidance of $255-$260 million, indicating a growth rate of 13%-15% without accounting for AviClear contributions.

Cutera Inc. (CUTR) announced the presentation of clinical data for its FDA-cleared device AviClear at the American Society for Laser Medicine and Surgery meeting held between April 27-30, 2022, in San Diego, CA. AviClear is a 1726 nm laser designed to treat mild, moderate, and severe acne. The device's efficacy and safety were showcased through two oral and four poster presentations by expert physicians. Following FDA clearance in March 2022, AviClear is set for national availability in the U.S. in 2022, with select treatments starting in April.

Cutera, Inc. (NASDAQ: CUTR), a prominent provider of aesthetic and dermatology solutions, will announce its first-quarter 2022 financial results on May 10, 2022, after market close. A conference call to discuss these results is scheduled for 1:30 p.m. PT (4:30 p.m. ET) on the same day. Interested parties can join by calling 1-800-381-7839 (domestic) or +1-416-981-0157 (international) using Conference ID: 22017471. The call will also be available as a live webcast on Cutera's website shortly after the call concludes.

Cutera and Synchrony have formed an exclusive partnership to enhance patient financing for dermatology practices in the U.S., facilitating access to AviClear, the first FDA-cleared laser treatment for acne. This collaboration aims to alleviate cost concerns for millions of acne sufferers by allowing practices to offer CareCredit payment options, making treatments more accessible. This initiative is expected to boost patient confidence and address the emotional impact of acne, providing a valuable resource for families seeking effective acne solutions.

Cutera, a leader in dermatology solutions, has announced the first patient treatment with AviClear, the sole FDA-cleared device for treating mild to severe acne. This follows its FDA 510k clearance on March 24, 2022. AviClear provides effective acne treatment with no need for pain therapy, using a unique handpiece that enhances patient comfort. The rollout of AviClear is set for 2022 across the United States, accompanied by the Avi360 partnership, which facilitates integration into dermatology practices.

AviClear has received FDA 510(k) clearance, becoming the first energy-based device approved for treating mild, moderate, and severe acne. This laser treatment is designed to provide a safe, prescription-free solution, targeting the source of acne by suppressing sebum production. Clinical trials demonstrate that AviClear not only reduces existing acne but also improves future breakout patterns, showing long-term efficacy without requiring pain mitigation. Cutera aims to introduce AviClear to physicians in the U.S. throughout 2022, revolutionizing acne treatment.